Drugs Of Abuse (DOA) Testing Market 2025

> Drugs Of Abuse (DOA) Testing Market Size

The global drugs of abuse (DOA) testing market reached a value of nearly $7,299.12 million in 2024, having grown at a compound annual growth rate (CAGR) of 6.24% since 2019. The market is expected to grow from $7,299.12 million in 2024 to $11,319.89 million in 2029 at a rate of 9.17%. The market is then expected to grow at a CAGR of 8.46% from 2029 and reach $16,988.98 million in 2034. Growth in the historic period resulted from increasing consumption of alcohol, rising drug abuse cases, increase in forensic and criminal investigations and rise in workplace safety concerns. Factors that negatively affected growth in the historic period were infrastructure and regulatory challenges and lack of standardization. Going forward, growing healthcare awareness, rise in road safety concerns, rise in drug smuggling and trafficking and expansion of rehabilitation and treatment centers. Factor that could hinder the growth of the drugs of abuse (DOA) testing market in the future include high costs of advanced testing equipment and risk of false positives and negatives.

Drugs Of Abuse (DOA) Testing Market Drivers

The key drivers of the drugs of abuse (doa) testing market include: Growing Healthcare Awareness Growing healthcare awareness is anticipated to drive the growth of the drugs of abuse testing market during the forecast period. Healthcare awareness involves understanding, recognizing, and gaining knowledge about various health-related topics, including diseases, preventive measures, treatment options, and overall wellness. The widespread adoption of digital health platforms has enhanced healthcare awareness by providing accessible and reliable health information and educational resources. This growing awareness is fueling the drugs of abuse testing market by educating the public about the health risks associated with substance abuse, promoting preventive measures, and encouraging early detection through regular screening in workplaces, schools, and healthcare settings. For example, according to Experian Information Solutions, Inc., a US-based information services company, gym membership spending increased by 11% during Christmas and 4% in January 2025, reflecting a strong commitment to fitness early in the year. Additionally, individuals aged 35-44 experienced a 7% rise in fitness spending, emphasizing their focus on health and well-being. Therefore, the increasing healthcare awareness is expected to boost the growth of the drugs of abuse testing market.

Drugs Of Abuse (DOA) Testing Market Restraints

The key restraints on the drugs of abuse (doa) testing market include: High Costs Of Advanced Testing Equipment High costs of advanced testing equipment are expected to hamper the growth of the drugs of abuse testing market in the forecast period. Advanced testing equipment often requires significant upfront investment, making it expensive for smaller clinics, hospitals, or testing labs to adopt such technologies. Additionally, these devices may require regular maintenance and calibration, further adding to the financial burden. For many institutions, these costs may not be sustainable, limiting their ability to conduct frequent or wide-scale testing. For instance, in March 2024, according to the Electronic Engineering Video Blog (EEVblog), an Australia-based provider of content for electronics engineers and enthusiasts, in some cases, the cost of advanced testing equipment, particularly for electromagnetic compatibility (EMC) testing, can surpass $50,000 for compliance testing. Therefore, the high costs of advanced testing equipment will restrict the growth of the drugs of abuse testing market in the forecast period.

Drugs Of Abuse (DOA) Testing Market Trends

Major trends shaping the drugs of abuse (doa) testing market include: Revolutionizing Drug Testing With Mass Spec Solution For Enhanced Accuracy And Efficiency Leading companies in the drugs of abuse testing market are focusing on developing innovative solutions, such as mass spec solutions, to enhance the accuracy, sensitivity, and speed of drug testing processes. Mass Spec solution in drugs of abuse testing refers to the use of mass spectrometry (MS) technology for detecting and quantifying drugs and their metabolites in various biological samples, such as blood, urine, saliva, and hair. For instance, in December 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched its cobas Mass Spec solution, which has received CE mark approval, marking a significant milestone in making clinical mass spectrometry widely available. This solution includes the cobas i 601 analyzer and the first Ionify reagent pack, enabling automated and standardized testing for over 60 analytes, including steroid hormones, vitamin D metabolites, and drugs of abuse. By integrating various technologies into a single platform, Roche aims to enhance diagnostic accuracy and efficiency in routine laboratories, facilitating earlier detection of therapeutic changes in patients. The cobas Mass Spec solution is expected to transform clinical diagnostics by providing faster, more precise results, ultimately improving patient care worldwide. Innovative Drugs Of Abuse Reagents Enhance Accuracy And Portability In Testing Leading companies in the drugs of abuse testing market are focusing on developing innovative solutions, such as drugs of abuse reagents, to improve the accuracy, speed, and reliability of drug screening tests. Drugs of abuse reagents are chemical substances or testing solutions used in laboratory assays to detect illicit or controlled substances in biological samples like urine, blood, or saliva. For example, in April 2023, MIP Discovery (Tozaro), a UK-based developer of advanced reagents, introduced its first drugs of abuse detection product targeting norfentanyl, the primary urinary metabolite of fentanyl, to combat the growing opioid crisis. Leveraging its proprietary nanoMIP technology, MIP Discovery produces synthetic, animal-free affinity reagents with high specificity and sensitivity, ideal for portable testing applications. This innovation addresses a critical need for accurate, field-deployable tests capable of detecting fentanyl metabolites.

Opportunities And Recommendations In The Drugs Of Abuse (DOA) Testing Market

Opportunities –Recommendations-